JCT  Vol.4 No.2 , April 2013
Spontaneous Regression of a Histologically Proven Cutaneous Squamous Cell Carcinoma
Abstract: Introduction: The rate of squamous cell carcinoma spontaneous regression (SR) remains unknown because incidences are rare and underreported. Case Report: We present a case of a 92-year-old Caucasian female who was found to have a 1 cm lesion on her nose. Pathologic evaluation supported the diagnosis of a moderately-differentiated squamous cell carcinoma. The patient refused treatment and returned with no clinical evidence of disease several months later. The lesion spontaneously regressed without excision. Discussion: Frequency of SR of malignancies has been estimated to occur 1 in 80,000 to 100,000 cases [1]. The biologic mechanisms of SR in malignancies remain unclear. Further investigations into the mechanisms of SR may identify potential treatment strategies for cancer.
Cite this paper: S. Sengupta, J. Arocho and T. Christopher Windham, "Spontaneous Regression of a Histologically Proven Cutaneous Squamous Cell Carcinoma," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 546-548. doi: 10.4236/jct.2013.42068.

[1]   G. B. Challi and H. J. Stam, “The Spontaneous Regression of Cancer: A Review of Cases from 1900 to 1987,” Acta Oncologica, Vol. 29, No. 5, 1990, pp. 545-550. doi:10.3109/02841869009090048

[2]   F. H. Igney and P. H. Krammer, “Immune Escape of Tumors: Apoptosis Resistance and Tumor Counterattack,” Journal of Leukocyte Biology, Vol. 71, No. 9, 2002, pp. 907-920.

[3]   Z. C. Ding and G. Zhou, “Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Anti-Tumor Effects,” Clinical Development. Immunology, Vol. 2012, 2012, Article ID: 890178. doi:10.1155/2012/890178

[4]   R. J. Papac, “Spontaneous Regression of Cancer,” Cancer Treatment Reviews, Vol. 22, No. 6, 1996, pp. 395-423. doi:10.1016/S0305-7372(96)90023-7

[5]   W. Y. Chang, “Complete Spontaneous Regression of Cancer: Four Case Reports, Review of Literature, and Discussion of Possible Mechanisms Involve,” Hawaii Medical Journal, Vol. 59, 2000, pp. 379-385.

[6]   B. O’Regan and C. Hirschberg, “Spontaneous Remission. An Annotated Bibliography,” Institute of Noetic Sciences, Sausalito, 1996.

[7]   J. Li, K. Wang, T. D. Jensen, S. T. Li, P. M. De Angelis, S. Kolvraa, C. Proby, O. Forslund, L. Bolund and O. P. Clausen, “Array Comparative Genomic Hybridization of Keratoacanthomas and Squamous Cell Carcinomas: Different Patterns of Genetic Aberrations Suggest Two Distinct Entities,” Journal of Investigative Dermatology, Vol. 132, No. 8, 2012. doi:10.1038/jid.2012.104

[8]   S. D. Cline and P. C. Hanawalt, “Who’s on First in the Cellular Response to DNA Damage?” Nature Reviews Molecular Biology, Vol. 4, No. 5, 2003, pp. 361-373. doi:10.1038/nrm1101

[9]   F. J. Tefany, R. Barneston and C. Sta, “lmmunocytochemical Analysis of the Cellular Infiltrate in Primary Regressing and Non-Regressing Malignant Melanoma,” Journal of Investigative Dermatology, Vol. 97, No. 2, 1991, 197-202. doi:10.1111/1523-1747.ep12479662

[10]   L. Jennings and C. D. Schmults, “Management of HighRisk Cutaneous Squamous Cell Carcinoma,” Journal of Clinical Aesthetic Dermatology, Vol. 3, No. 4, 2010, pp. 39-48.

[11]   S. Mocellin, E. Wang and F. Marincola, “Cytokines and Immune Response in Tumor Microenvironment,” Journal of Immunotherapy, Vol. 24, No. 5, 2001, pp. 392-407. doi:10.1097/00 002371-200109000-00002

[12]   S. J. Kalapurakai, J. Malone, K. Robbins, L. Beuscher, J. Godwin and K. Rao, “Cetuximab in Refractory Skin Cancer Treatment,” Journal of Cancer, Vol. 3, 2012, pp. 257-261. doi:10.7150/jca.3491

[13]   M. Mancuso, D. Gallo, S. Leonardi, M. Pierdomenico, E. Pasquali, I. De Stefano, S. Rebessi, M. Tanori, G. Scambia1, V. Di Majo, V. Covelli, S. Pazzaglia and A. Saran, “Modulation of Basal and Squamous Cell Carcinoma by Endogenous Estrogen in Mouse Models of Skin Cancer,” Carcinogenesis, Vol. 30, No. 2, 2009, pp. 340-347. doi:10.1093/carcin/bgn243